Wood Dale, Illinois — AAR (NYSE: AIR) a leading provider of aviation services to commercial and government operators, announced today that BASF has appointed AAR as a preferred distributor of Maintenance Repair and Overhaul (MRO) services for Deoxo™ aircraft cabin ozone/volatile organic compounds (VOC) converters in compliance with the new abbreviated component maintenance manuals (ACMMs) released earlier this month.
As announced earlier this month, BASF has updated its ACMMs for the Deoxo™ portfolio for the Airbus A320, and A330/A340. The updated ACMMs redefine the test procedures and service methods for maintaining the converters to ensure continued industry-leading performance. Proper testing includes functional checks of both ozone conversion efficiency and change in air pressure through the converter. These functional checks are currently included in BASF’s MRO services, which have been managed by AAR since April 2019.
“The collaboration of the two industry leaders BASF and AAR will extend the availability of Deoxo ozone and ozone/VOC converters and better service customers around the world,” said Ying Wu, General Manager of BASF’s Clean Air Business.
“AAR is excited to further extend our partnership with BASF by continuing to support our shared customers and connecting them with critical MRO services that are fully compliant with the latest ACMM revisions”, said Eric Young, AAR SVP of OEM Solutions.
BASF Deoxo™ ozone and ozone/VOC converters catalytically remove ozone and certain odorous VOCs to deliver quality cabin air compliant with government regulations. As the leading company in aircraft ozone/VOC converters, BASF is developing new technology to further improve airplane cabin air quality for the health and safety of the crew and passengers. The air at high altitude contains significant levels of ozone. If left unchecked, atmospheric ozone enters the aircraft through air conditioning ducts. Ozone exposure is known to cause adverse health effects, including headaches, fatigue, shortness of breath, chest pain, coughing, and irritation of the eyes, nose or throat.